U lcerative colitis is a form of inflammatory bowel disease. It is a chronic relapsing condition affecting the colon and rectum and can cause a variety of symptoms, the commonest of which is bloody diarrhoea. Prompt diagnosis, as well as flare identification and management by primary care clinicians can improve patient outcomes such as disease progression and effects on quality of life.
The GP curriculum and ulcerative colitis Professional module 2.01: The GP consultation in practice requires GPs to: . Demonstrate focused questioning and examination to obtain sufficient relevant information to diagnose, manage and refer appropriately
. Formulate appropriate diagnoses, rule out serious illness, and manage clinical uncertainty
. Use the consultation to educate patients about self-management of acute and chronic disease and be able to direct them to appropriate sources for further education Clinical module 3.03: Care of acutely ill people requires GPs to:
. Know when it is safe and appropriate to manage a patient in the community and when the patient needs to be referred to hospital for assessment or admission
Clinical module 3.13: Digestive health requires GPs to:
. Demonstrate a systematic approach to investigating common digestive symptoms
. Have a good understanding of the impact of gastrointestinal symptoms and illness on patients, their families and their wider networks
Epidemiology
Ulcerative colitis is the most common form of inflammatory bowel disease, with a prevalence of 240 per 100 000 of the population. In contrast, Crohn's disease has a prevalence of 157 per 100 000. Ulcerative colitis is most commonly diagnosed in patients between the ages of 15 and 25 years, but there is a second smaller peak of incidence between the ages of 55 and 65 years. Men and women are equally affected. The global incidence of inflammatory bowel disease is highest in North America and Northern Europe (the prevalence being highest in Norway where 505 per 100 000 of the population have the condition), and lowest in Africa, South America and Asia. However, the global trend since the 1990s has been a levelling off of incidence in the former group of countries, and accelerating incidence in the latter (Ng et al., 2017) .
Pathogenesis and clinical course
Ulcerative colitis is a condition that causes inflammation confined to the rectum and colon, unlike Crohn's disease which can affect any part of the digestive tract. The inflammation occurs solely in the superficial mucosal lining in ulcerative colitis, which again differentiates it from Crohn's disease which can cause transmural inflammation. This accounts for the association between Crohn's disease and fistulae and stricturing disease, which is uncommon in ulcerative colitis. Inflammation generally begins in the rectum, and if it remains localised in this part of the bowel is termed proctitis. It can, however, extend more proximally in a confluent pattern in the colon, being termed proctosigmoiditis if it extends to the sigmoid colon, left-sided colitis to the splenic flexure, and extensive, or pancolitis, if it affects the entire colon. It is a relapsing-remitting condition, with up to 50% of patients experiencing a relapse annually. A small number of patients have a frequently relapsing, or chronic, continuous disease. Although the risk of undergoing surgery for patients with ulcerative colitis has decreased with the introduction of new medical therapies, the risk is still significant, and increases with duration of disease, with an estimated 15.6% of patients requiring surgery 10 years post-diagnosis (Frolkis et al., 2013) .
Causes
The causes of inflammatory bowel disease are not fully understood, but it is generally believed to be triggered in susceptible individuals by an abnormal immune response to a luminal antigen. It is therefore likely that both genetic and environmental factors have a role in the development of the disease. The role of genetic factors appears to be greater in Crohn's disease than ulcerative colitis; this conclusion is based on studies of monozygous twins where the concordance of Crohn's disease has been shown to be greater than that of ulcerative colitis (up to 50% in the former, as opposed to 18.8% in the latter) (Halfvarson et al., 2003; Spehlmann et al., 2008) . The growing incidence of inflammatory bowel disease in countries undergoing industrialisation lends support to an environmental trigger. Smoking is the most widely studied environmental factor, with smoking conferring a protective effect on the development of ulcerative colitis, and an increased risk of development of, and relapse in, Crohn's disease. Certain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics are recognised as risk factors for the development of inflammatory bowel disease, and it has been suggested that bowel infections may also represent a risk factor in certain individuals (Zhang and Li, 2014) .
Clinical features
The most common symptom of active ulcerative colitis is bloody diarrhoea. Associated features may include abdominal pain that is colicky in nature, urgency to defecate, tenesmus and pre-defecation pain. Nocturnal defecation is a feature that may raise suspicion of inflammatory bowel disease, as it is less common in functional bowel disorders. In severe active ulcerative colitis, systemic features may also be present, such as fever, tachycardia and malaise. Extraintestinal manifestations are less common presenting features, but occur in between 25 and 40% of patients with ulcerative colitis over the course of their disease. Extraintestinal conditions such as pauci-articular arthritis, erythema nodosum and episcleritis occur with increased disease activity, whereas others such as ankylosing spondylitis and uveitis follow a course independent of bowel disease activity. Primary sclerosing cholangitis and pyoderma gangrenosum can be seen in either active or quiescent disease (see Table 1 ).
Diagnosis
Ulcerative colitis should be suspected if the clinical features, described above, are present. History-taking should be directed at eliciting these symptoms, exploring any risk factors that may be present, such as medications (NSAIDs and antibiotics) and a family history of inflammatory bowel disease, and inquiring into other features and risk factors that may suggest an alternative diagnosis (see Box 1 and Box 2). If ulcerative colitis is suspected and history and examination do not suggest the need for urgent hospital assessment (an indication for this being suspected acute severe colitis), then investigations can be initiated in primary care. This would include blood tests (full blood count, renal function, thyroid function tests, coeliac screen, inflammatory markers, and bone profile) and stool microscopy and culture for infective causes. If these are normal, and ulcerative colitis is still suspected, a faecal calprotectin stool test to assess for bowel inflammation can help differentiate between organic and functional bowel symptoms.
If ulcerative colitis is suspected following clinical and biochemical assessment, referral to a gastroenterologist is required to confirm the diagnosis. The gold standard test for confirming the diagnosis is a colonoscopy with multiple biopsies to assess the extent and severity of the disease within the colon.
Faecal calprotectin
Calprotectin is a protein found in neutrophils. In inflammatory states within the bowel, it is released into the lumen and can . Risk factors (smoking, family history of inflammatory bowel disease)
. Recent travel .
Medications (NSAIDs and antibiotic use)
. Extraintestinal features (see Table 1 )
Diverticulitis
. Irritable bowel syndrome
Gastroenteritis
InnovAiT be detected in raised concentrations in stools. It can aid in the differentiation between inflammatory bowel disease and irritable bowel syndrome. Faecal calprotectin also has a role in monitoring disease activity, and is frequently used by secondary care teams to assess the response to treatment. For distinguishing between inflammatory bowel disease and irritable bowel syndrome, faecal calprotectin has been shown to have a sensitivity of 93% and specificity of 94% at a lower cut-off level of 50 mg/g. Levels greater than 150 mg/g raise the likelihood of inflammatory bowel disease, and would prompt urgent referral to secondary care for further assessment, generally with colonoscopy.
More recently, however, a new pathway with a lower cutoff of 100 mg/g and higher cut-off of 250 mg/g with clear guidance around how to manage an 'intermediate' result between these cut-off levels has been developed and piloted in the north of England; it is showing the potential to reduce the need for unnecessary and invasive procedures such as endoscopy, and enable GPs to more confidently diagnose and manage irritable bowel syndrome in the community.
It is important to be aware that faecal calprotectin can be raised in the presence of gastrointestinal infections, and therefore testing too early in the course of an illness or flare without excluding infections can lead to a false positive result. Furthermore, it is important to remember that it can be raised in people taking certain medications, including proton pump inhibitors and NSAIDs, and therefore, stopping these medications prior to testing is recommended.
Management

Flare management
Patients newly diagnosed with ulcerative colitis will usually have treatment initiated by specialist secondary care teams, with the aim of inducing remission. However, patients with known ulcerative colitis may present to their GP with symptoms suggestive of active disease, these include bloody diarrhoea and increased frequency of defecation. Confirming the flare is important, as other conditions can cause similar symptoms (see Box 1), and it is important to avoid the use of steroids in those with infective or functional symptoms. Confirming and assessing the severity of the flare can be done through clinical examination, as well as blood and stool testing (stool microscopy and culture, and faecal calprotectin).
Management options for ulcerative colitis depend largely on disease activity, which can be assessed using an objective assessment tool such as the Truelove-Witts criteria (see Table 2 ). Hospital admission is advised for patients with severe disease, whereas those with mild-to-moderate disease can be managed in the community or on an outpatient basis.
Primary care management of a confirmed mild-to-moderate disease flare includes increasing the patient's maintenance dose of oral aminosalicylate (see Box 3). The treatment dose of these medications is generally twice the maintenance dose, depending on the preparation used. This can be combined 
Maintaining remission
The long-term aim of treatment in ulcerative colitis is to maintain remission of disease and to minimise the frequency and severity of disease flares. Aminosalicylates, most commonly mesalazine, are used as first-line therapy in patients with mild-to-moderate ulcerative colitis (see Box 3) either in oral or rectal form, depending on disease location. Treatment is life-long and non-compliance has been shown to increase the risk of disease flares. There is also evidence to suggest that long-term treatment with aminosalicylate drugs can reduce colorectal cancer risk by up to 75% (Mowat et al., 2010) . To aid compliance, single daily dosing has been shown to be as effective as multiple daily dosing regimens for maintaining remission. Second-line treatment for ulcerative colitis includes immunosupressant medications such as Azathioprine and Mercaptopurine, and biologic agents such as infliximab, adalimumab, vedolizumab and tofacitinib. The indications for starting these medications can be seen in Box 4. These will be started by secondary care, and there should be local protocols in place for the monitoring of these medications. Bone marrow suppression and liver toxicity can occur with immunosupressant medications, whereas biologic agents can cause hepatotoxicity and immunosupression, increasing the patient's susceptibility to infection. Azathioprine and mercaptopurine can also increase the risk of non-melanoma skin cancer, with biologic agents increasing the risk of certain forms of lymphoma.
Surgery
Surgery is required in a small, but significant, number of patients with ulcerative colitis, as seen earlier. Some hospitals will therefore offer joint clinics run by gastroenterologists and colorectal surgeons to ensure that patients are fully counselled about the options available to them. The options include panproctocolectomy with end-ileostomy formation, or restorative proctocolectomy with Ileo-anal pouch also known as Ilealpouch anal anastomosis (IPAA). The choice of procedure will be guided by patient preference, and clinical criteria such as the presence of dysplasia and sphincter function. Frequently, surgery is being performed once medical therapy has failed, and given that patients are often taking high doses of corticosteroids prior to the procedure, complications such as sepsis and poor healing can occur.
Pregnancy
Pregnancy is an important area to consider, given that ulcerative colitis is often diagnosed in late teen and young adult years. The Faculty of Sexual and Reproductive Health has published guidance relating to inflammatory bowel disease and contraception and conception (Faculty of Sexual and Reproductive Health, 2016) . The absorption of the oral contraception is not affected by ulcerative colitis, unlike in Crohn's disease where absorption can be reduced. Ulcerative colitis does not appear to reduce fertility in either men or women, however, certain medications such as infliximab and sulfasalazine can reduce sperm motility. There is also evidence Box 3. Aminosalicylates (mesalazine, sulfasalazine, balsalazide, olsalazine).
Various formulations have been developed with the aim of optimising delivery of the drug to the site of inflammation, such as pH-dependent, colonic-bacteria-activated, and enteric-coated formulations. Examples of these include Pentasa Õ , Mezavent Õ , Salofalk Granules Õ , and Colazide Õ . Their mechanism of action is thought to be due to a negative effect on proinflammatory leukotrienes and prostaglandins. Common side effects include diarrhoea, headache, nausea and rash. Side effects are more common in those taking sulfasalazine than mesalazine, which is generally well-tolerated. Nephrotoxicity is a rare side-effect; therefore, annual renal function testing for those on long-term aminosalicylates is good practice. showing that surgery for ulcerative colitis, especially IPAA, can increase infertility three-fold in women. Well-controlled disease is recommended pre-conception and throughout pregnancy, therefore pre-conception counselling should be provided by the patient's gastroenterologist. Folic acid at a dose of 400 mg is sufficient in women with ulcerative colitis, but should be increased if the patient is taking sulfasalazine as this can affect folate absorption. If either partner is taking methotrexate, pregnancy should be prevented by the use of effective contraception both during and for at least 3 months after treatment has ended. Azathioprine can usually be continued throughout pregnancy, but should be discussed with the patient and secondary care. The British National Formulary advises that pregnancy should also be prevented during treatment with biologic agents and for 6 months after treatment has ended. However, some biologic drugs can safely be given in the first two trimesters, and so pre-conception planning and early liaison with secondary care is important.
Colorectal cancer
The risk of colorectal cancer is significantly elevated in patients with ulcerative colitis. The risk is similar in patients with Crohn's disease. This increased risk is likely to be due to chronic colonic inflammation causing sequential genomic alterations in the mucosa of the colon leading to the accelerated development of colorectal cancer. The annual incidence of colorectal cancer is 18% in those with ulcerative colitis 30 years following diagnosis (Lakatos and Lakatos, 2008) . The progression from diagnosis with ulcerative colitis to colorectal cancer appears to be accelerated in those over the age of 40 years at time of diagnosis (Karvellas et al., 2007) . As a result, people with inflammatory bowel disease should have surveillance colonoscopies on a regular basis once they have had the condition for 8 to 10 years. The frequency of this surveillance will vary from between 1 and 5 years, depending on various disease factors such as disease extent, associated conditions (especially primary sclerosing cholangitis), and family history of colorectal cancer.
Anxiety
Raised anxiety levels are found in up to 40% of patients with inflammatory bowel disease, and this increases to 80% in those experiencing a flare, according to a recent meta-analysis (Bannaga and Selinger, 2015) . A number of risk factors for increased anxiety have been identified, including severe and active disease, increasing age, episodes of hospitalisation and surgery (Goodhand et al., 2012) . Patients with ulcerative colitis can also display symptoms of irritable bowel syndrome, as there is a link between anxiety disorders and functional gastrointestinal disorders. If symptoms persist in patients with no objective evidence of active inflammation, treatment for functional symptoms should be considered (Bannaga and Selinger, 2015) . Assessing for, and managing, concomitant anxiety disorders should be a part of chronic disease management in those with ulcerative colitis. Interventions such as cognitive behavioural therapy can be helpful, as can informal support from charities such as Crohn's and Colitis UK, and in some situations medications, in particular selective serotonin reuptake inhibitors, may be required.
Osteoporosis
The risk of osteoporosis and osteopenia in patients with ulcerative colitis is significantly higher than the general population. This is believed to be due to frequent use of corticosteroids, as well as a direct effect of proinflammatory cytokines on bone metabolism, and more specifically by promoting bone resorption through increased osteoclast activity (Piodi et al., 2014) . The National Institute for Health and Clinical Excellence (NICE) recognises both corticosteroid use and gastrointestinal disease, including ulcerative colitis, as risk factors for osteoporosis and fragility fractures. As such, assessment of a patient's risk of fragility fracture with the use of a validated risk assessment tool such as FRAX is recommended. This should be assessed on an episodic basis in patients with ulcerative colitis. The co-prescription of calcium/vitamin D supplements during corticosteroid use is a useful strategy to reduce the loss of bone.
Advice and support
Inflammatory bowel disease nurse specialists are a valuable resource for both GPs and patients. If a patient becomes unwell between appointments with their secondary care team, many inflammatory bowel disease services across the UK provide an advice line for both patients and healthcare professionals. The advice lines are run by nurse specialists who can provide support and advice in non-emergency situations. For details of your local nurse specialist and advice line, you can visit the 'Find an IBD nurse specialist' section of the Crohn's and Colitis UK website. The RCGP has also developed a toolkit for healthcare professionals to provide a 'one-stop shop' for advice on all aspects of inflammatory bowel disease care.
KEY POINTS
. Core features include bloody diarrhoea and abdominal pain
. Patients with acute severe colitis need urgent admission to hospital
. Consider aminosalicylates as first-line treatment for mild-to-moderate flares of ulcerative colitis
. Steroids when appropriate should be started at 40 milligrams prednisolone, reducing by 5 milligrams weekly for a total course of 8 weeks
. Non-compliance with aminosalicylate maintenance therapy is associated with disease relapse
. People with ulcerative colitis are at significantly higher risk of colorectal cancer than the general population
